Table 1 Baseline characteristic data of the studied patients
Variables | Studied patients (N = 240) |
|---|---|
Age | |
Mean ± SD | 52.9 ± 8.8 years |
Gender | |
Male | 143 (59.6%) |
Female | 97 (40.4%) |
Previous HCV treatment | |
Treatment naïve | 240 (100%) |
Treatment experienced | 0 (0.0%) |
Viral load, IU/L | |
Median (IQR) | 5455685 (496040–18102824) |
Fibroscan value, kPa | |
Mean ± SD | 25.8 ± 4.5 |
Serum ALT, IU/L | |
Median (IQR) | 62.5 (40.0–98.5) |
Serum albumin, g/dL | |
Mean ± SD | 3.54 ± 0.46 |
Total bilirubin, mg/dL | |
Mean ± SD | 1.42 ± 0.60 |
INR | |
Mean ± SD | 1.19 ± 0.22 |
Child-Pugh score | |
Mean ± SD | 7.3 ± 1.5 |
Serum creatinine, mg/dL | |
Mean ± SD | 1.1 ± 0.3 |
AFP, ng/mL | |
Median (IQR) | 21.0 (18.0–30.0) |
Platelet count, × 109 per liter | |
Mean ± SD | 131.5 ± 37.1 |
Treatment regimen | |
Sofosbuvir + daclatasvir | 240 (100.0%) |
Other regimens | 0 (0.0%) |
Serious adverse effects | 0 (0.0%) |
Discontinuation of treatment | 0 (0.0%) |